Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/54—Nitrogen and either oxygen or sulfur atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/426—1,3-Thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

• the present disclosure relates to a) crystalline forms of ⁇ 2-[3-cyclohexyl-3-(trans-4- propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid ("Compound I” or "API”); b) pharmaceutical compositions, comprising one or more crystalline forms of ⁇ 2-[3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid, and optionally, a pharmaceutically acceptable carrier; and c) methods of treating a type of diabetes mellitus and other disorders by administering one or more crystalline forms of ⁇ 2-[3-cyclohexyl-3-(trans-4- propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid to a subject in need thereof.
• GK Glucokinase
• HGP hepatic glucose production
• Compound I is an oral, small molecule, liver selective glucokinase activator that improves glycemic control and may not induce hypoglycemia, dyslipidemia, or pathological increases of glycogen and TG in the liver at therapeutically relevant doses. (Vella et al., Science Translational Medicine 16 Jan 2019).
• GK activators have characteristics affording the best potential to become useful therapeutics. Some of these characteristics include high affinity at the glucokinase, duration of glucokinase activation, oral bioavailability, tissue distribution, and stability (e.g., ability to formulate or crystallize, shelf life). Favorable characteristics can lead to improved safety, tolerability, efficacy, therapeutic index, patient compliance, cost efficiency, manufacturing ease, etc.
• the present disclosure relates to a crystalline form of ⁇ 2-[3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid.
• the crystalline form is anhydrous.
• the crystalline form is solvated.
• the present disclosure relates to crystalline form of ⁇ 2- [3 -cyclohexyl-3 - (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid of Formula (I)
• the present disclosure relates to a crystalline form of ⁇ 2-[3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid, characterized by an XRPD pattern having peaks at 16.9 ⁇ 0.2, 17.4 ⁇ 0.2, and 20.1 ⁇ 0.2 degrees two theta.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is characterized by an endothermic peak with onset at about 160°C, as determined by DSC.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is characterized by an IR pattern having peaks at 1099.7 ⁇ 2.0, 1158.0 + 2.0, and 1313.2 + 2.0 cm 1 .
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is characterized by a 13 C solid state NMR substantially as shown in FIG. 4.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid has a unit cell that indexes as primitive monoclinic.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]- thiazol-5-ylsulfanyl ⁇ -acetic acid has a unit cell with an a value of about 10.193 A, a b value of about 12.256 A, and a c value of about 18.991 A.
• the crystalline form of ⁇ 2- [3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid has a unit cell with a volume of about 2370.9 A 3 .
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is Form A.
• the present disclosure relates to a crystalline form of ⁇ 2-[3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid, characterized by an XRPD pattern having peaks at 11.0 ⁇ 0.2, 11.6 ⁇ 0.2, and 17.8 ⁇ 0.2 degrees two theta.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is characterized by an endothermic peak with onset at about 166°C, as determined by DSC.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is characterized by an IR pattern having peaks at 1310.1 ⁇ 2.0, 1514.4 ⁇ 2.0, and 1661.3 ⁇ 2.0 cm 1 .
• the crystalline form of of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is characterized by a 13 C solid state NMR substantially as shown in FIG. 8.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid has a unit cell that indexes as primitive monoclinic.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]- thiazol-5-ylsulfanyl ⁇ -acetic acid has a unit cell with an a value of about 11.028 A, a b value of about 11.933 A, and a c value of about 18.737 A.
• the crystalline form of ⁇ 2- [3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid has a unit cell with a volume of about 2449.0 A 3 .
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is Form B.
• the present disclosure relates to a crystalline form of ⁇ 2-[3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid, characterized by an XRPD pattern having peaks at 4.3 ⁇ 0.2, 17.4 ⁇ 0.2, and 21.6 ⁇ 0.2 degrees two theta.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is characterized by an endothermic peak with onset at about 149°C, as determined by DSC.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is a dichloromethane solvate.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid has a unit cell that indexes as primitive monoclinic.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]- thiazol-5-ylsulfanyl ⁇ -acetic acid has a unit cell with an a value of about 5.541 A, a b value of about 13.040 A, and a c value of about 40.818 A.
• the crystalline form of ⁇ 2- [3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid has a unit cell with a volume of about 2947.6 A 3 .
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is Form C.
• the present disclosure relates to a crystalline form of ⁇ 2-[3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid, characterized by an XRPD pattern having peaks at 5.3 ⁇ 0.2, 8.7 ⁇ 0.2, and 26.4 ⁇ 0.2 degrees two theta.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is characterized by an endothermic peak with onset at about 147°C, as determined by DSC.
• the crystalline form of of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is characterized by a 13 C solid state NMR substantially as shown in FIG. 13.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is Form D.
• the present disclosure relates to a crystalline form of ⁇ 2-[3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid, characterized by an XRPD pattern having peaks at 5.8 ⁇ 0.2, 17.9 ⁇ 0.2, and 18.9 ⁇ 0.2 degrees two theta.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is characterized by an endothermic peak with onset at about 171°C, as determined by DSC.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is Form E.
• the present disclosure relates to a crystalline form of ⁇ 2-[3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid, characterized by an XRPD pattern having peaks at 3.8 ⁇ 0.2, 9.5 ⁇ 0.2, and 16.8 ⁇ 0.2 degrees two theta.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is Form F.
• the present disclosure relates to a crystalline form of ⁇ 2-[3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid, characterized by an XRPD pattern having peaks at 3.4 ⁇ 0.2, 21.2 ⁇ 0.2, and 21.9 ⁇ 0.2 degrees two theta.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is Form G.
• the present disclosure relates to a crystalline form of ⁇ 2-[3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid, characterized by an XRPD pattern having peaks at 3.8 ⁇ 0.2, 5.3 ⁇ 0.2, and 8.5 ⁇ 0.2 degrees two theta.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is Form H.
• the present disclosure relates to a crystalline form of ⁇ 2-[3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid, characterized by an XRPD pattern having peaks at 5.0 ⁇ 0.2, 16.8 ⁇ 0.2, and 18.8 ⁇ 0.2 degrees two theta.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is Form I.
• the present disclosure relates to a crystalline form of ⁇ 2-[3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid, characterized by an XRPD pattern having peaks at 5.9 ⁇ 0.2, 17.4 ⁇ 0.2, and 18.8 ⁇ 0.2 degrees two theta.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is characterized by an endothermic peak with onset at about 164°C, as determined by DSC.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is Form J.
• the crystalline form is substantially free of other polymorphic forms. In some aspects, the crystalline form has a polymorphic purity of at least about 80%.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)- ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, and Form J.
• the crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5- ylsulfanyl ⁇ -acetic acid is Form A.
• the present disclosure relates to a pharmaceutical composition
• a pharmaceutical composition comprising any one or more of the crystalline forms discussed above and a pharmaceutically acceptable carrier, diluent, excipient, or a mixture thereof.
• the present disclosure relates to a method of treating a type of diabetes mellitus or other disorders, where the method comprises administering the pharmaceutical composition discussed above to a patient in need thereof.
• the type of diabetes mellitus is type 1 diabetes.
• the type of diabetes mellitus is type 2 diabetes.
• the pharmaceutical composition is administered orally. In some aspects, the pharmaceutical composition is administered as a tablet. In some aspects, the patient is administered up to about 2000 mg of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]- thiazol-5-ylsulfanyl ⁇ -acetic acid daily.
• the present disclosure provides methods of making a crystalline form of ⁇ 2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid where the crystalline form is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, and Form J.
• FIG. 1 is a powder X-ray diffraction pattern ("XRPD") corresponding to crystalline Form A.
• FIG. 2A is a differential scanning calorimetry thermogram ("DSC") corresponding to crystalline Form A.
• FIG. 2B is a thermogravimetric analysis thermogram ("TGA") corresponding to crystalline Form A.
• FIG. 3 is an Infrared (“IR”) spectrum corresponding to crystalline Form A.
• FIG. 4 is a 13 C solid state NMR corresponding to crystalline Form A.
• FIG. 5 is an XRPD corresponding to crystalline Form B.
• FIG. 6A is a DSC corresponding to crystalline Form B.
• FIG. 6B is a TGA corresponding to crystalline Form B.
• FIG. 7 is an IR spectrum corresponding to crystalline Form B.
• FIG. 8 is a 13 C solid state NMR corresponding to crystalline Form B.
• FIG. 9 is an XRPD corresponding to crystalline Form C.
• FIG. 10A is a DSC corresponding to crystalline Form C.
• FIG. 10B is a TGA corresponding to crystalline Form C.
• FIG. 11 is an XRPD corresponding to crystalline Form D.
• FIG. 12A is a DSC corresponding to crystalline Form D.
• FIG. 12B is a TGA corresponding to crystalline Form D.
• FIG. 13 is a 13 C solid state NMR corresponding to crystalline Form D.
• FIG. 14 is an XRPD corresponding to crystalline Form E.
• FIG. 15A is a DSC corresponding to crystalline Form E.
• FIG. 15B is a TGA corresponding to crystalline Form E.
• FIG. 16 is an XRPD corresponding to crystalline Form F.
• FIG. 17 is an XRPD corresponding to crystalline Form G.
• FIG. 18 is an XRPD corresponding to crystalline Form H.
• FIG. 19 is an XRPD corresponding to crystalline Form I.
• FIG. 20 is an XRPD corresponding to crystalline Form J.
• FIG. 21 A is a DSC corresponding to crystalline Form J.
• FIG. 21B is a TGA corresponding to crystalline Form J. DETAILED DESCRIPTION OF THE INVENTION
• Compound I refers to the chemical compound ⁇ 2-[3-cyclohexyl-3-(trans-4- propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid.
• subject refers to an animal, including, but not limited to, a primate (e.g., human), cow, sheep, goat, horse, dog, cat, rabbit, rat, or mouse.
• primate e.g., human
• cow, sheep, goat horse
• dog cat
• rabbit rat
• patient are used interchangeably herein in reference, for example, to a mammalian subject, such as a human subject.
• treat means to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or alleviating the cause(s) of the disorder, disease, or condition itself.
• pharmaceutically acceptable carrier refers to a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material.
• each component is "pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit/risk ratio.
• the terms “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain aspects, the term “about” or “approximately” means within 1, 2, 3, or 4 standard deviations. In certain embodiments, the term “about” or “approximately” means within 50%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.05% of a given value or range.
• active ingredient and “active substance” refer to a compound, which is administered, alone or in combination with one or more pharmaceutically acceptable excipients, to a subject for treating, delaying onset of, or ameliorating one or more symptoms of a condition, disorder, or disease.
• active ingredient and active substance may be an optically active isomer of a compound described herein.
• solvate refers to a compound provided herein or a salt thereof, which further includes a stoichiometric or non- stoichiometric amount of solvent bound by non- covalent intermolecular forces.
• the solvent is water
• the solvate is a hydrate.
• the solvent includes ethanol
• the compound can be an ethanol solvate.
• polymorph refers to a crystalline form of a compound or a salt, hydrate, or solvate thereof, in a particular crystal packing arrangement. All polymorphs have the same elemental composition.
• crystalline refers to a solid state form which consists of orderly arrangement of structural units. Different crystalline forms of the same compound, or a salt, hydrate, or solvate thereof, arise from different packing of the molecules in the solid state, which results in different crystal symmetries and/or unit cell parameter. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility.
• Crystalline forms are most commonly characterized by X-ray powder diffraction (XRPD).
• XRPD pattern of reflections (peaks, typically expressed in degrees 2-theta) is commonly considered a fingerprint of a particular crystalline form.
• the relative intensities of the XRPD peaks can widely vary depending on, inter alia, the sample preparation technique, crystal size distribution, filters, the sample mounting procedure, and the particular instrument employed. In some instances, new peaks may be observed or existing peaks may disappear, depending on the type of instrument or the settings.
• any particular peak in an XRPD pattern may appear as a singlet, doublet, triplet, quartet, or multiplet, depending on the type of instrument or the settings, the sensitivity of the instrument, measuring conditions, and/or purity of the crystalline form.
• any particular peak in an XRPD may appear in a symmetric shape or in an asymmetric shape, e.g., having a shoulder.
• instrument variation and other factors can affect the 2-theta values. A skilled artisan understanding these variations is capable of discriminating or ascertaining the defining features or characteristics of a particular crystal form using XRPD, as well as using other known physicochemical techniques.
• anhydrate or “anhydrous” as applied to a compound refers to a solid state wherein the compound contains no structural water within the crystal lattice.
• a peak positional reproducibility is associated with the values of degree-20 (XRPD), ppm ( 13 C solid state NMR), and cm 1 (IR). Accordingly, it will be understood that all peaks disclosed herein have the value disclosed ⁇ the peak positional reproducibility associated with each analytical technique.
• the XRPD peak positional reproducibility is ⁇ 0.2 expressed in degree-20.
• the 13 C NMR peak positional reproducibility is ⁇ 0.2 ppm.
• the IR peak positional reproducibility is ⁇ 2 cm 1 .
• the present disclosure relates to a crystalline form of ⁇ 2-[3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid.
• the crystalline form is anhydrous as determinded by 1 H NMR.
• the crystalline form is solvated as determinded by 1 H NMR.
• the present disclosure relates to crystalline form of ⁇ 2- [3 -cyclohexyl-3 - (trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl ⁇ -acetic acid of Formula (I)
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 16.9 ⁇ 0.2, 17.4 ⁇ 0.2, and 20.1 ⁇ 0.2 degrees two theta.
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 8.7 ⁇ 0.2, 16.9 ⁇ 0.2, 17.4 ⁇ 0.2, and 20.1 ⁇ 0.2 degrees two theta.
• the crystalline form of Compound I is characterized by an XRPD pattern substantially as shown in FIG. 1.
• the crystalline form of Compound I is characterized by the following XRPD pattern in Table 1 expressed in terms of the degree 20 and relative intensities:
• the crystalline form of Compound I is characterized by an endothermic peak with onset at about 160°C, as determined by DSC. In one aspect, the crystalline form of Compound I is characterized by a DSC profile substantially as shown in FIG. 2A. In one aspect, the crystalline form of Compound I is characterized by a TGA profile substantially as shown in FIG. 2B.
• the crystalline form of Compound I is characterized by an IR pattern having peaks at 1099.7 ⁇ 2.0, 1158.0 ⁇ 2.0, and 1313.2 ⁇ 2.0 cm 1 . In one aspect, the crystalline form of Compound I is characterized by an IR pattern having peaks at 1099.7 ⁇ 2.0, 1158.0 ⁇ 2.0, 1238.7 ⁇ 2.0, and 1313.2 ⁇ 2.0 cm 1 . In one aspect, the crystalline form of Compound I is characterized by the following IR peaks in Table 2.
• the crystalline form of Compound I is characterized by an IR pattern substantially as shown in FIG. 3.
• the crystalline form of Compound I is characterized by a 13 C solid state NMR substantially as shown in FIG. 4.
• the crystalline form is anhydrous as determinded by 1 H NMR.
• the crystalline form of Compound I has a unit cell that indexes as primitive monoclinic. In another aspect, the crystalline form of Compound I has a unit cell with an a value of about 10.193 A, a b value of about 12.256 A, and a c value of about 18.991 A. In another aspect, the crystalline form of Compound I has a unit cell with a volume of about 2370.9 A 3 .
• the crystalline form of Compound I is Form A.
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 11.0 ⁇ 0.2, 11.6 ⁇ 0.2, and 17.8 ⁇ 0.2 degrees two theta.
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 11.0 ⁇ 0.2, 11.6 ⁇ 0.2, 17.8 ⁇ 0.2, and 21.1 ⁇ 0.2 degrees two theta.
• the crystalline form of Compound I is characterized by an XRPD pattern substantially as shown in FIG. 5.
• the crystalline form of Compound I is characterized by the following XRPD pattern in Table 3 expressed in terms of the degree 2Q and relative intensities:
• the crystalline form of Compound I is characterized by an endothermic peak with onset at about 166°C, as determined by DSC. In one aspect, the crystalline form of Compound I is characterized by a DSC profile substantially as shown in FIG. 6A. In one aspect, the crystalline form of Compound I is characterized by a TGA profile substantially as shown in FIG. 6B.
• the crystalline form of Compound I is characterized by an IR pattern having peaks at 1310.1 ⁇ 2.0, 1514.4 ⁇ 2.0, and 1661.3 ⁇ 2.0 cm 1 . In one aspect, the crystalline form of of Compound I is characterized by an IR pattern having peaks at 1097.3 ⁇ 2.0, 1310.1 ⁇ 2.0, 1541.4 ⁇ 2.0, and 1661.3 ⁇ 2.0 cm 1 . In one aspect, the crystalline form of Compound I is characterized by the following IR peaks in Table 4.
• the crystalline form of Compound I is characterized by an IR pattern substantially as shown in FIG. 7.
• the crystalline form of of Compound I is characterized by a 13 C solid state NMR substantially as shown in FIG. 8.
• the crystalline form is anhydrous as determinded by 1 H NMR.
• the crystalline form of Compound I has a unit cell that indexes as primitive monoclinic. In another aspect, the crystalline form of Compound I has a unit cell with an a value of about 11.028 A, a b value of about 11.933 A, and a c value of about 18.737 A. In another aspect, the crystalline form of Compound I has a unit cell with a volume of about 2449.0 A 3 .
• the crystalline form of Compound I is Form B.
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 4.3 ⁇ 0.2, 17.4 ⁇ 0.2, and 21.6 ⁇ 0.2 degrees two theta. In one aspect, the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 4.3 ⁇ 0.2, 8.0 ⁇ 0.2, 17.4 ⁇ 0.2, and about 21.6 ⁇ 0.2 degrees two theta.
• the crystalline form of Compound I is characterized by an XRPD pattern substantially as shown in FIG. 9. In one aspect, the crystalline form of Compound I is characterized by the following
• the crystalline form of Compound I is characterized by an endothermic peak with onset at about 149°C, as determined by DSC. In one aspect, the crystalline form of
• Compound I is characterized by a DSC profile substantially as shown in FIG. 10A.
• the crystalline form of Compound I is characterized by a TGA profile substantially as shown in FIG. 10B.
• the crystalline form is a solvate as determinded by 1 H NMR.
• the crystalline form of Compound I is a dichloromethane solvate.
• the crystalline form of Compound I has a unit cell that indexes as primitive monoclinic. In another aspect, the crystalline form of Compound I has a unit cell with an a value of about 5.541 A, a b value of about 13.040 A, and a c value of about 40.818 A. In another aspect, the crystalline form of Compound I has a unit cell with a volume of about 2947.6 A 3 .
• the crystalline form of Compound I is Form C.
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 5.3 ⁇ 0.2, 8.7 ⁇ 0.2, and 26.4 ⁇ 0.2 degrees two theta. In one aspect, the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 5.3 ⁇ 0.2, 8.7 ⁇ 0.2, 18.2 ⁇ 0.2, and 26.4 ⁇ 0.2 degrees two theta.
• the crystalline form of Compound I is characterized by an XRPD pattern substantially as shown in FIG. 11.
• the crystalline form of Compound I is characterized by the following XRPD pattern in Table 6 expressed in terms of the degree 20 and relative intensities:
• the crystalline form of Compound I is characterized by an endothermic peak with onset at about 147°C, as determined by DSC. In one aspect, the crystalline form of Compound I is characterized by a DSC profile substantially as shown in FIG. 12A. In one aspect, the crystalline form of Compound I is characterized by a TGA profile substantially as shown in FIG. 12B.
• the crystalline form of Compound I is characterized by a 13 C solid state NMR substantially similar to FIG. 13.
• the crystalline form of Compound I is Form D.
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 5.8 ⁇ 0.2, 17.9 ⁇ 0.2, and 18.9 ⁇ 0.2 degrees two theta. In one aspect, the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 5.8 ⁇ 0.2, 17.9 ⁇ 0.2, 18.9 ⁇ 0.2, and 20.7 ⁇ 0.2 degrees two theta.
• the crystalline form of Compound I is characterized by an XRPD pattern substantially as shown in FIG. 14.
• the crystalline form of Compound I is characterized by the following XRPD pattern in Table 7 expressed in terms of the degree 20 and relative intensities: Table 7
• the crystalline form of Compound I is characterized by an endothermic peak with onset at about 171°C, as determined by DSC. In one aspect, the crystalline form of Compound I is characterized by a DSC profile substantially as shown in FIG. 15 A. In one aspect, the crystalline form of Compound I is characterized by a TGA profile substantially as shown in FIG. 15B.
• the crystalline form of Compound I is Form E. F. Crystalline Form F
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 3.8 ⁇ 0.2, 9.5 ⁇ 0.2, and 16.8 ⁇ 0.2 degrees two theta. In one aspect, the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 3.8 ⁇ 0.2, 9.5 ⁇ 0.2, 16.8 ⁇ 0.2, and 17.9 ⁇ 0.2 degrees two theta.
• the crystalline form of Compound I is characterized by an XRPD pattern substantially as shown in FIG. 16. In one aspect, the crystalline form of Compound I is characterized by the following XRPD pattern in Table 8 expressed in terms of the degree 2Q and relative intensities:
• the crystalline form of Compound I is Form F.
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 3.4 ⁇ 0.2, 21.2 ⁇ 0.2, and 21.9 ⁇ 0.2 degrees two theta. In one aspect, the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 3.4 ⁇ 0.2, 21.2 ⁇ 0.2, 21.9 ⁇ 0.2, and 22.4 ⁇ 0.2 degrees two theta.
• the crystalline form of Compound I is characterized by an XRPD pattern substantially as shown in FIG. 17. In one aspect, the crystalline form of Compound I is characterized by the following
• the crystalline form of Compound I is Form G.
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 3.8 ⁇ 0.2, 5.3 ⁇ 0.2, and 8.5 ⁇ 0.2 degrees two theta. In one aspect, the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 3.8 ⁇ 0.2, 5.3 ⁇ 0.2, 8.5 ⁇ 0.2, and 15.9 ⁇ 0.2 degrees two theta.
• the crystalline form of Compound I is characterized by an XRPD pattern substantially as shown in FIG. 18.
• the crystalline form of Compound I is characterized by the following XRPD pattern in Table 10 expressed in terms of the degree 20 and relative intensities: Table 10
• the crystalline form of Compound I is Form H. I. Crystalline Form I
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 5.0 ⁇ 0.2, 16.8 ⁇ 0.2, and 18.8 ⁇ 0.2 degrees two theta.
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 5.0 ⁇ 0.2, 15.9 ⁇ 0.2, 16.8 ⁇ 0.2, and 18.8 ⁇ 0.2 degrees two theta.
• the crystalline form of Compound I is characterized by an XRPD pattern substantially as shown in FIG. 19.
• the crystalline form of Compound I is characterized by the following XRPD pattern in Table 11 expressed in terms of the degree 2Q and relative intensities:
• the crystalline form of Compound I is Form I.
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 5.9 ⁇ 0.2, 17.4 ⁇ 0.2, and 18.8 ⁇ 0.2 degrees two theta.
• the present disclosure relates to a crystalline form of Compound I, characterized by an XRPD pattern having peaks at 5.9 ⁇ 0.2, 12.7 ⁇ 0.2, 17.4 ⁇ 0.2, and 18.8 ⁇ 0.2 degrees two theta.
• the crystalline form of Compound I is characterized by an XRPD pattern substantially as shown in FIG. 20.
• the crystalline form of Compound I is characterized by an endothermic peak with onset at about 164°C, as determined by DSC. In one aspect, the crystalline form of Compound I is characterized by a DSC profile substantially as shown in FIG. 21 A. In one aspect, the crystalline form of Compound I is characterized by a TGA profile substantially as shown in FIG. 21B.
• the crystalline form of Compound I is characterized by the following XRPD pattern in Table 12 expressed in terms of the degree 2Q and relative intensities:
• the crystalline form of Compound I is Form J. In some aspects, any one of the crystalline forms discussed above is substantially free of other polymorphic forms. In some aspects, the crystalline form has a polymorphic purity of at least about 80%. In some aspects, the crystalline form has a polymorphic purity of at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.
• the crystalline form of Compound I is selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, and Form J. In one aspect, the crystalline form of Compound I is Form A.
• the crystalline form of Compound I is a mixture of two or more forms selected from the group consisting of Form A, Form B, Form C, Form D, Form E, Form F,
• the crystalline form of Compound I is a mixture of two or more forms selected from the group consisting of Form A, Form B, and Form C.
• the crystalline form of Compound I is a mixture of Form A and Form B, where Form B is the major form and Form A is the minor form.
• the present disclosure provides a methods of making a crystalline form of Compound I where the crystalline form is selected from the group consisting of Form A,
• Form B Form C, Form D, Form E, Form F, Form G, Form H, Form I, and Form J.
• One or more methods to prepare Forms A-J are provided in Expermental Section herein.
• the present disclosure relates to a pharmaceutical composition
• a pharmaceutical composition comprising the crystalline form of any one of Forms A-J of Compound I and a pharmaceutically acceptable carrier, diluent, or excipients, or a mixture thereof.
• the pharmaceutical composition comprises the crystalline form of any one of Forms A-J of Compound I.
• compositions comprising the crystalline form of any one of Forms A-J of Compound I can be in a form suitable for oral use, for example, as tablets, troches, lozenges, dispersible powders or granules, or hard or soft capsules.
• Compositions intended for oral use can be prepared according to any known method, and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents, and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
• the pharmaceutical composition can be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g., through the use of a patch) routes.
• parenteral such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques
• rectal intranasal, topical or transdermal (e.g., through the use of a patch) routes.
• the pharmaceutical composition comprises about 100 mg to about 1500 mg, about 100 mg to about 1400 mg, about 100 mg to about 1300 mg, about 100 mg to about 1200 mg, about 100 mg to about 1100 mg, about 100 mg to about 1000 mg, about 100 mg to about 900 mg, about 100 mg to about 800 mg, about 100 mg to about 700 mg, about 100 mg to about 600 mg, about 100 mg to about 500 mg, about 100 mg to about 400 mg, about 100 mg to about 300 mg, about 100 mg to about 200 mg, or about 100 mg to about 150 mg of the crystalline form of any one of Forms A-J of Compound I disclosed herein.
• the pharmaceutical composition comprises about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, or about 1500 mg of the crystalline form of any one of Forms A-J of Compound I disclosed herein.
• the pharmaceutical composition is an oral tablet.
• the oral tablet comprises about 0.1 mg to 2000 mg of the crystalline form of any one of Forms A-J 2- [3-cyclohexyl-3 -(trans-4-propoxy-cyclohexyl) -ureido] -thiazol-5 -ylsulfanyl ⁇ -acetic acid.
• the oral tablet comprises about 1 mg to about 2000 mg of the crystalline form of any one of Forms A-J of Compound I.
• the oral tablet comprises about 1 mg to about 1000 mg of the crystalline form of any one of Forms A-J of Compound I.
• the oral tablet comprises about 100 mg to about 800 mg of the crystalline form of any one of Forms A-J of Compound I. In some aspects, the oral tablet comprises about 50 mg to about 400 mg of the crystalline form of any one of Forms A-J of Compound I. In some aspects, the oral tablet comprises about 100 mg to about 400 mg of the crystalline form of any one of Forms A-J of Compound I. In some aspects, the oral tablet comprises about 100 mg to about 300 mg of the crystalline form of any one of Forms A-J ofCompound I. In some aspects, the oral tablet comprises about 500 mg to about 1000 mg of the crystalline form of any one of Forms A-J ofCompound I.
• the oral tablet comprises about 0.1 mg, about 0.5 mg, about 1 mg, about 5 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 1150 mg, about 1200 mg, about 1250 mg, about 1300 mg, about 1350 mg, about 1400 mg, about
• the oral tablet comprises 800 mg of the crystalline form of any one of Forms A-J ofCompound I. In some aspects, the oral tablet comprises 400 mg of the crystalline form of any one of Forms A-J of Compound I. In some aspects, the oral tablet comprises 300 mg of the crystalline form of any one of Forms A-J of Compound I. In some aspects, the oral tablet comprises about 200 mg of the crystalline form of any one of Forms A-J of Compound I.
• the present disclosure relates to a method of treating a type of diabetes mellitus, wherein the method comprises administering the pharmaceutical composition discussed above to a patient in need thereof.
• the method can comprise administering a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of any one of Forms A-J of Compound I.
• the type of diabetes mellitus is type 1 diabetes.
• the type of diabetes mellitus is type 2 diabetes.
• the type of diabetes is one or two types of type 1 diabetes and type 2 diabetes.
• the patient is being treated with an insulin therapy.
• the insulin therapy is a continuous insulin infusion.
• the insulin therapy is a continuous subcutaneous insulin infusion.
• the insulin therapy is a multiple daily doses of insulin.
• the present disclosure provides a method for the treatment of glucokinase-deficiency mediated conditions or diseases, or conditions benefiting from an increase in glucokinase activity, comprising administering to a subject in need thereof a compound or a pharmaceutical composition of the present disclosure.
• the present disclosure provides a method for treatment of metabolic disorders, for blood glucose lowering, for the treatment of hyperglycemia, for the treatment of hypoglycemia for the treatment of impaired glucose tolerance (IGT), for the treatment of Syndrome X, for the treatment of impaired fasting glucose (IFG), for delaying the progression of impaired glucose tolerance (IGT) to type 2 diabetes, for delaying the progression of non-insulin requiring type 2 diabetes to insulin requiring type 2 diabetes, for the treatment of dyslipidemia, for the treatment of hyperlipidemia, for the treatment of hypertension, for lowering of food intake, for appetite regulation, for the treatment of obesity, for regulating feeding behavior, or for enhancing the secretion of enteroincretins, comprising administering to a subject in need of such treatment a compound or a pharmaceutical composition of the present disclosure.
• the present disclosure provides a method for the preservation of beta cell mass and function comprising administering to a subject in need of such treatment a compound or a pharmaceutical composition of the present disclosure.
• the present disclosure provides a method of preserving and/or increasing beta-cell mass and function in a subject having undergone pancreatic islet transplantation comprising administering to a subject in need of such treatment a compound or a pharmaceutical composition of the present disclosure.
• the present disclosure provides a method of improving liver function and/or survival in subjects undergoing liver transplantation comprising administering to a subject in need of such treatment a compound or a pharmaceutical composition of the present disclosure.
• the administration occurs before, during or after transplantation, or any combination thereof.
• the present disclosure provides a method of preventing diabetic ketoacidosis or reducing the occurrence of diabetic ketoacidosis events in a subject comprising administering to a subject in need of such treatment a compound or a pharmaceutical composition of the present disclosure.
• the pharmaceutical compositions provided herein can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or intraarterial (e.g., via catheter), ICV, intracistemal injection or infusion, subcutaneous injection, or implant), inhalation, nasal, vaginal, rectal, sublingual, and/or topical (e.g., transdermal or local) routes of administration, and can be formulated alone or together in suitable dosage unit with a pharmaceutically acceptable vehicle, carrier, diluent, excipient, or a mixture thereof, appropriate for each route of administration ⁇
• the pharmaceutical composition is administered orally.
• the pharmaceutical compositions provided herein can be provided in solid, semisolid, or liquid dosage forms for oral administration.
• oral administration also includes buccal, lingual, and sublingual administration.
• Suitable oral dosage forms include, but are not limited to, tablets, capsules, pills, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, granules, bulk powders, effervescent or non-effervescent powders or granules, solutions, emulsions, suspensions (e.g., aqueous or oil suspensions), wafers, sprinkles, elixirs, syrups, bolus, electuaries, or pastes.
• the pharmaceutical composition is administered as a tablet.
• the dose can be in the form of one, two, three, four, five, six, or more sub-doses that are administered at appropriate intervals per day.
• the dose or sub-doses can be administered in the form of dosage units containing from about 1 mg to about 2000 mg, from about 10 mg to about 2000 mg, from about 100 mg to about 1500 mg, from about 200 mg to about 1500 mg, from about 200 mg to about 1500 mg, from about 300 mg to about 1500 mg, from about 400 mg to about 1500 mg, from about 500 mg to about 1500 mg, from about 500 mg to about 1000 mg, or from about 500 mg to about 800 mg of the crystalline form of any one of Forms A-J per dosage unit.
• the dose or subdoses can be administered in the form of dosage units containing about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, or about 2000 mg of the crystalline form of any one of Forms A-J disclosed herein.
• the patient is administered about 0.1 mg to about 2000 mg of the crystalline form of any one of Forms A-J of Compound I daily. In some aspects, the patient is administered about 1 mg to about 2000 mg of the crystalline form of any one of Forms A-J of Compound I daily. In some aspects, the patient is administered about 100 mg to about 800 mg of the crystalline form of any one of Forms A-J of Compound I daily. In some aspects, the patient is administered about 50 mg to about 400 mg of the crystalline form of any one of Forms A-J of Compound I daily. In some aspects, the patient is administered about 100 mg to about 400 mg of the crystalline form of any one of Forms A-J of Compound I daily.
• the patient is administered about 100 mg to about 300 mg of the crystalline form of any one of Forms A-J of Compound I daily. In some aspects, the patient is administered about 500 mg to about 1000 mg of the crystalline form of any one of Forms A-J of Compound I daily.
• the patient is administered about 0.1 mg, about 0.5 mg, about 1 mg, about 5 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 500 mg, about 550 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 1150 mg, about 1200 mg, about 1250 mg, about 1300 mg, about 1350 mg, about 1400 mg, about 1450 mg, about 1500 mg, about 1550 mg, about 1600 mg, about 1650 mg, about 1700 mg, about 1750 mg, about 1800 mg, about 1850 mg, about 1900 mg, about 1950 mg, or about 2000 mg, of the crystalline form of any one of Forms A-J of Compound
• the patient is administered about 800 mg of the crystalline form of any one of Forms A-J of Compound I once daily. In some aspects, the patient is administered about 400 mg of the crystalline form of any one of Forms A-J of Compound I once daily. In some aspects, the patient is administered about 300 mg of the crystalline form of any one of Forms A-J of Compound I once daily. In some aspects, the patient is administered about 200 mg of the crystalline form of any one of Forms A-J of Compound I once daily. In some aspects, the patient is administered about 100 mg of the crystalline form of any one of Forms A-J of Compound I once daily.
• Slurry triburation experiments target the stable forms, including stable solvates and hydrates.
• the slurry-trituration experiments were conducted by stirring solids of Compound I in specified solvents and solvent mixtures at various temperatures for 7 days (elevated temperature) or 14-18 days (ambient and sub-ambient temperatures).
• 7 days elevated temperature
• 14-18 days ambient and sub-ambient temperatures
• Solutions of starting material were allowed to partially evaporate or evaporate to dryness at ambient or elevated temperature from open vials for fast evaporation (EE) or from vials covered with aluminum foil with pin holes for slow evaporation (SE). Prior to evaporation, solutions were filtered at ambient or elevated temperature using 0.2 pm nylon filters.
• Solutions of starting material were prepared in specified solvents at elevated temperature using a hot plate for heating. These were typically hot-filtered through a 0.2 pm nylon filter into warm receiving vials. The vials were either quickly transferred into a sub-ambient temperature bath (typically dry ice/acetone) for crash cooling (CC), removed from the hot place for fast cooling (FC) or the heat was turned off to allow for slow cooling (SC). If solids precipitated, they were isolated cold by vacuum filtration. If the solution remained clear, the sample was either kept at sub-ambient temperatures or further crystallization techniques were applied.
• CC crash cooling
• FC fast cooling
• SC slow cooling
• Solids were suspended in specified solvents. The suspensions were then agitated at ambient or set temperature. After a given amount of time solids were isolated.
• Method d Solvent/ Anti-Solvent Precipitation Solutions of starting material were prepared at ambient or elevated temperature and filtered using 0.2 pm nylon filters. They were then mixed with appropriate anti-solvents at elevated temperature. If no solids were observed, the samples were either cooled to ambient or sub-ambient temperatures or other crystallization techniques applied.
• Table 15 summarizes the preparation conditions for selected materials.
• Table 16 summarizes the drying conditions for selected materials Table 16
• thermodynamically most stable anhydrous form among Form A, Form D, Form B, and Form E, competitive slurries were performed in acetone at 2-8°C, ambient temperature, and 45 °C.
• XRPD patterns were collected with a PANalytical X’Pert PRO MPD or Empyrean diffractometer using an incident beam of Cu radiation produced using an Optix long, fine-focus source.
• An elliptically graded multilayer mirror was used to focus Cu Ka X-ray radiation through the specimen and onto the detector.
• a silicon specimen NIST SRM 640e was analyzed to verify the observed position of the Si (111) peak is consistent with the NIST-certified position.
• a specimen of the sample was sandwiched between 3-pm-thick films and analyzed in transmission geometry.
• a beam-stop, short antiscatter extension, and antiscatter knife-edge were used to minimize the background generated by air.
• Soller slits for the incident and diffracted beams were used to minimize broadening from axial divergence. Diffraction patterns were collected using a scanning position-sensitive detector (X’Celerator) located 240 mm from the specimen and Data Collector software v. 5.5.
• X’Celerator scanning position-sensitive detector
• TGA/DSC combination analyses were performed using a Mettler Toledo TGA/DSC3+ analyzer. Temperature and enthalpy adjustments were performed using indium, tin, and zinc, and then verified with indium. Balance was verified with calcium oxalate.
• the sample was placed in an aluminum pan. The pan was hermetically sealed, the lid pierced, then inserted into the TG furnace. A weighed aluminum pan configured as the sample pan was placed on the reference platform. The furnace was heated under nitrogen.
• Moisture sorption/desorption data were collected on a Surface Measurement System DVS Intrinsic instrument. Samples were not dried prior to analysis. For the as received lot, sorption and desorption data were collected over a range from 5% to 95% RH at 10% RH increments. The equilibrium criterion used for analysis was less than 0.0100% weight change in 5 minutes with a maximum equilibration time of 3 hours. Data were not corrected for the initial moisture content of the samples.
• Hot stage microscopy was performed using a Linkam hot stage (FUR 600) mounted on a Leica DM LP microscope equipped with a SPOT InsightTM color digital camera. Temperature calibrations were performed using USP melting point standards. Samples were placed on a cover glass, and a second cover glass was placed on top of the sample. As the stage was heated, each sample was visually observed using a 20x objective, 0.40 NA with crossed polarizers and a first order red compensator. Images were captured using SPOT software (v. 4.5.9).
• PLM was performed using a Leica DM LP microscope equipped with a Spot Insight color camera. Crossed-polarized light was used with a first order red compensator. Various objectives were used to view the sample. Samples were suspended either in mineral oil or the dispersant selected for the method. Images were acquired at ambient temperature using Spot Advanced software (v.4.5.9). Micrometer bars were inserted onto the images as a reference for size. Particle sizes were measured using an eyepiece reticle scale calibrated using a NIST traceable stage micrometer.
• the spectrum was acquired with phase modulated (SPINAL-64) high power 1 H decoupling during the acquisition time using a 1 H pulse width of 2.6 ps (90°), a ramped amplitude cross polarization contact time of 5 ms, a 30 ms acquisition time, a 10 second delay between scans, a spectral width of 45 kHz with 2678 data points, and 1600 co-added scans.
• the free induction decay (FID) was processed using Agilent Vnmr.I 3.2A software with 65536 points and an exponential line broadening factor of 10 Hz to improve the signal-to-noise ratio.
• the first three data points of the FID were back predicted using the VNMR linear prediction algorithm to produce a flat baseline.
• the chemical shifts of the spectral peaks were externally referenced to the carbonyl carbon resonance of glycine at 176.5 ppm.
• FT-IR Fourier transform infrared
• DTGS deuterated triglycine
• the high-resolution XRPD pattern of Compound I was indexed using X'Pert High Score Plus 2.2a (2.2.1) in this study. Indexing and structure refinement are computational studies. Agreement between the allowed peak positions, marked with red bars, and the observed peaks indicates a consistent unit cell determination. Successful indexing of the pattern indicates that the sample is composed primarily of a single crystalline phase. Space groups consistent with the assigned extinction symbol, unit cell parameters, and derived quantities are tabulated below each figure showing tentative indexing solution. To confirm the tentative indexing solution, the molecular packing motifs within the crystallographic unit cells must be determined. No attempts at molecular packing were performed.
• Forms A, B, D, and E are anhydrous materials of Compound I. Among them, Form A is likely the most stable form within 2-8 °C to 45 °C based on results from competitive slurries.
• Form C is likely a DCM solvate which desolvates into Form D.
• Form F is also a solvated material and converts to Form D upon drying.
• Form I could represent a family of iso-structural solvates. It converts to Form E or solids similar to Form E upon drying.
• Forms G and H are disordered crystalline materials and could be solvates. They become disordered upon drying.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Diabetes (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Epidemiology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Thiazole And Isothizaole Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=78846441

Family Applications (1)

Country Status (9)

Cited By (3)

Families Citing this family (1)

Citations (4)

Family Cites Families (2)

• 2021
  • 2021-06-07 CN CN202511373032.0A patent/CN121202809A/zh active Pending
  • 2021-06-07 EP EP21821691.9A patent/EP4161639A4/en active Pending
  • 2021-06-07 KR KR1020237000609A patent/KR20230048501A/ko active Pending
  • 2021-06-07 CA CA3181665A patent/CA3181665A1/en active Pending
  • 2021-06-07 AU AU2021289591A patent/AU2021289591A1/en active Pending
  • 2021-06-07 WO PCT/US2021/036082 patent/WO2021252309A1/en not_active Ceased
  • 2021-06-07 MX MX2022015524A patent/MX2022015524A/es unknown
  • 2021-06-07 CN CN202180056233.1A patent/CN116056760A/zh active Pending
  • 2021-06-07 US US18/000,908 patent/US20230219910A1/en active Pending
  • 2021-06-07 JP JP2023519156A patent/JP2023530785A/ja active Pending
• 2022
  • 2022-12-06 MX MX2026000786A patent/MX2026000786A/es unknown

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events